Amylyx (AMLX) CMO Camille Bedrosian Sells 10,028 Shares

What Happened

• Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals (AMLX), sold a total of 10,028 shares on 2026-09-10 in two transactions. She disposed of 7,947 shares at a weighted-average price of $32.21 (proceeds ~$256,004) and 2,081 shares at a weighted-average price of $33.09 (proceeds ~$68,864), for total proceeds of about $324,868. These sales were reported as open-market/private sales (code S) and were automatic to satisfy tax withholding obligations tied to vesting equity.

Key Details

• Transaction date: 2026-09-10; Form 4 filed: 2026-09-14 (four days after the trades).
• Prices reported: $32.21 (weighted avg for the 7,947-share sale; individual trades ranged $31.76–$32.68) and $33.09 (weighted avg for the 2,081-share sale; trades ranged $32.85–$33.29).
• Total shares sold: 10,028; total proceeds ≈ $324,868.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes: F1 notes the sales were automatic to cover tax withholding and not at the Reporting Person’s discretion; F2 and F3 explain the weighted-average pricing and give the per-trade price ranges.
• Filing timeliness: Form 4 was submitted four days after the transactions; Form 4s are typically due within two business days, so investors may note the reporting delay.

Context

• These trades were tax-withholding related (automatic sales upon vesting), which is routine and generally not viewed as an expression of confidence or concern about the stock by the insider. For retail investors, purchase transactions tend to be more informative about insider sentiment; automatic withholding sales are common following awards vesting.